{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T22:23:12Z","timestamp":1794090192734,"version":"4.8.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024678","name":"Center for Clinical and Translational Research, Kyushu University","doi-asserted-by":"publisher","award":["A171"],"award-info":[{"award-number":["A171"]}],"id":[{"id":"10.13039\/501100024678","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024678","name":"Center for Clinical and Translational Research, Kyushu University","doi-asserted-by":"publisher","award":["A105"],"award-info":[{"award-number":["A105"]}],"id":[{"id":"10.13039\/501100024678","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008965","name":"Takahashi Industrial and Economic Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008965","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K24379"],"award-info":[{"award-number":["23K24379"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["15K09574"],"award-info":[{"award-number":["15K09574"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23791140"],"award-info":[{"award-number":["23791140"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18K08435"],"award-info":[{"award-number":["18K08435"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005865","name":"Mochida Memorial Foundation for Medical and Pharmaceutical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008667","name":"SENSHIN Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008670","name":"Terumo Foundation for Life Sciences and Arts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.antiviral.2026.106552","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:13:35Z","timestamp":1791501215000},"page":"106552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Identification of novel HIV-1 capsid protein (CA) inhibitors (ACAi-010 and ACAi-024) that promote hyper-stabilization of HIV-1 CA in vitro"],"prefix":"10.1016","volume":"255","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0516-9502","authenticated-orcid":false,"given":"Masayuki","family":"Amano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7589-9514","authenticated-orcid":false,"given":"Tomofumi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikazu","family":"Miyakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotomo","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2026.106552_bib1","doi-asserted-by":"crossref","first-page":"10957","DOI":"10.1128\/JVI.01369-06","article-title":"In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat)","volume":"80","author":"Adamson","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2026.106552_bib7","doi-asserted-by":"crossref","first-page":"9806","DOI":"10.1038\/s41598-019-46082-2","article-title":"Amino-acid inserts of HIV-1 capsid (CA) induce CA degradation and abrogate viral infectivity: insights for the dynamics and mechanisms of HIV-1 CA decomposition","volume":"9","author":"Amano","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2026.106552_bib2","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1128\/AAC.01413-06","article-title":"A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against Multiple-PI-resistant human immunodeficiency virus in vitro","volume":"51","author":"Amano","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2026.106552_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-12052-9","article-title":"GRL-09510, a unique P2-Crown-Tetrahydrofuranylurethane-Containing HIV-1 protease inhibitor, maintains its favorable antiviral activity against highly-drug-resistant HIV-1 variants in vitro","volume":"7","author":"Amano","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2026.106552_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00466-19","article-title":"Novel central nervous system (CNS)-targeting protease inhibitors for drug-resistant HIV infection and HIV-associated CNS complications","volume":"63","author":"Amano","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2026.106552_bib5","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1128\/AAC.01428-16","article-title":"A modified P1 moiety enhances in vitro antiviral activity against various multi-drug-resistant HIV-1 variants and in vitro CNS penetration properties of a novel nonpeptidic protease inhibitor, GRL-10413","volume":"60","author":"Amano","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2026.106552_bib3","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1128\/AAC.02189-12","article-title":"GRL-0519, A novel Oxatricyclic-Ligand-Containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of Multi-PI-Resistant HIV-1 variants in vitro","volume":"57","author":"Amano","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2026.106552_bib4","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1128\/AAC.04757-14","article-title":"A novel tricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor, GRL-0739, effectively inhibits the replication of multidrug-resistant HIV-1 variants and has a desirable central nervous system penetration property in vitro","volume":"59","author":"Amano","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2026.106552_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01715-21","article-title":"Fluorine-modifications contribute to potent antiviral activity against highly drug-resistant HIV-1 and favorable blood-brain barrier (BBB) penetration property of novel central nervous system (CNS)-Targeting HIV-1 protease inhibitors in vitro","volume":"66","author":"Amano","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2026.106552_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01804-22","article-title":"Structural and mechanistic bases of viral resistance to HIV-1 capsid inhibitor lenacapavir","volume":"13","author":"Bester","year":"2022","journal-title":"mBio"},{"key":"10.1016\/j.antiviral.2026.106552_bib11","doi-asserted-by":"crossref","first-page":"8233","DOI":"10.1073\/pnas.1401455111","article-title":"Cryo-electron microscopy of tubular arrays of HIV-1 gag resolves structures essential for immature virus assembly","volume":"111","author":"Bharat","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2026.106552_bib12","doi-asserted-by":"crossref","first-page":"18625","DOI":"10.1073\/pnas.1419945112","article-title":"Structural basis of HIV-1 capsid recognition by PF74 and CPSF6","volume":"111","author":"Bhattacharya","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2026.106552_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001220","article-title":"HIV capsid is a tractable target for small molecule therapeutic intervention","volume":"6","author":"Blair","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2026.106552_bib14","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1021\/acsomega.2c06784","article-title":"Synthesis of selenoesters via aldol condensation and\/or conjugate reduction and their antiviral activities","volume":"8","author":"Boateng","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.antiviral.2026.106552_bib15","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2009.10.010","article-title":"Structural convergence between Cryo-EM and NMR reveals intersubunit interactions critical for HIV-1 capsid function","volume":"139","author":"Byeon","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2026.106552_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01039-21","article-title":"A small molecule, ACAi-028, with Anti-HIV-1 activity targets a novel hydrophobic pocket on HIV-1 capsid","volume":"65","author":"Chia","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2026.106552_bib17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.virol.2013.02.008","article-title":"Nup153 and Nup98 bind the HIV-1 core and contribute to the early steps of HIV-1 replication","volume":"440","author":"Di Nunzio","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2026.106552_bib18","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1021\/jm000292e","article-title":"Prediction of drug absorption using multivariate statistics","volume":"43","author":"Egan","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2026.106552_bib19","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/372359a0","article-title":"Specific incorporation of cyclophilin A into HIV-1 virions","volume":"372","author":"Franke","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2026.106552_bib20","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0092-8674(00)81823-1","article-title":"Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid","volume":"87","author":"Gamble","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2026.106552_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1021\/cc9800071","article-title":"A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases","volume":"1","author":"Ghose","year":"1999","journal-title":"J. Comb. Chem."},{"key":"10.1016\/j.antiviral.2026.106552_bib22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1126\/science.aaa5936","article-title":"STRUCTURAL VIROLOGY. X-ray crystal structures of native HIV-1 capsid protein reveal conformational variability","volume":"349","author":"Gres","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2026.106552_bib23","doi-asserted-by":"crossref","first-page":"5614","DOI":"10.1038\/s41467-023-41197-7","article-title":"Multidisciplinary studies with mutated HIV-1 capsid proteins reveal structural mechanisms of lattice stabilization","volume":"14","author":"Gres","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2026.106552_bib24","series-title":"HIV Sequence Compendium","year":"2014"},{"key":"10.1016\/j.antiviral.2026.106552_bib25","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1128\/JVI.03043-14","article-title":"Identification of capsid mutations that alter the rate of HIV-1 uncoating in infected cells","volume":"89","author":"Hulme","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2026.106552_bib26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jmb.2007.07.070","article-title":"Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein","volume":"373","author":"Kelly","year":"2007","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.antiviral.2026.106552_bib27","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.molcel.2005.01.002","article-title":"Domain swapping and retroviral assembly","volume":"17","author":"Kingston","year":"2005","journal-title":"Mol. Cell"},{"key":"10.1016\/j.antiviral.2026.106552_bib28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.antiviral.2026.106552_bib29","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1128\/JVI.76.14.6900-6908.2002","article-title":"Kinetic analysis of the role of intersubunit interactions in human immunodeficiency virus type 1 capsid protein assembly in vitro","volume":"76","author":"Lanman","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2026.106552_bib31","article-title":"Lenacapavir disrupts HIV-1 core integrity while stabilizing the capsid lattice","volume":"122","author":"Li","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2026.106552_bib30","doi-asserted-by":"crossref","first-page":"13555","DOI":"10.1073\/pnas.2234683100","article-title":"PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in gag processing","volume":"100","author":"Li","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2026.106552_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.antiviral.2026.106552_bib33","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1128\/AAC.01784-09","article-title":"Phenotypic susceptibility to bevirimat in isolates from HIV-1-Infected patients without prior exposure to bevirimat","volume":"54","author":"Margot","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2026.106552_bib34","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/infdis\/jiaf050","article-title":"Resistance analyses in heavily treatment-experienced people with HIV treated with the novel HIV capsid inhibitor lenacapavir after 2 years","volume":"231","author":"Margot","year":"2025","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2026.106552_bib35","doi-asserted-by":"crossref","first-page":"25185","DOI":"10.1074\/jbc.M110.114256","article-title":"Uncoating of human immunodeficiency virus type 1 requires prolyl isomerase Pin1","volume":"285","author":"Misumi","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2026.106552_bib36","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1021\/jm015507e","article-title":"Simple selection criteria for drug-like chemical matter","volume":"44","author":"Muegge","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2026.106552_bib37","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1128\/JVI.76.11.5435-5451.2002","article-title":"Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design?","volume":"76","author":"Novitsky","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2026.106552_bib38","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1128\/AAC.02560-15","article-title":"Identification and characterization of BMS-955176, a second-generation HIV-1 maturation inhibitor with improved potency, antiviral spectrum, and gag polymorphic coverage","volume":"60","author":"Nowicka-Sans","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2026.106552_bib39","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.cell.2009.04.063","article-title":"X-ray structures of the hexameric building block of the HIV capsid","volume":"137","author":"Pornillos","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2026.106552_bib40","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nature09640","article-title":"Atomic-level modelling of the HIV capsid","volume":"469","author":"Pornillos","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2026.106552_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002896","article-title":"CPSF6 defines a conserved capsid interface that modulates HIV-1 replication","volume":"8","author":"Price","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2026.106552_bib42","doi-asserted-by":"crossref","first-page":"6110","DOI":"10.1128\/AAC.01420-13","article-title":"GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of Multi-PI-Resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration","volume":"57","author":"Salcedo G\u00f3mez","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2026.106552_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002439","article-title":"HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiency","volume":"7","author":"Schaller","year":"2011","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2026.106552_bib44","doi-asserted-by":"crossref","DOI":"10.1093\/bioinformatics\/btad577","article-title":"A machine learning-based quantitative model (LogBB_Pred) to predict the blood-brain barrier permeability (logBB value) of drug compounds","volume":"39","author":"Shaker","year":"2023","journal-title":"Bioinformatics"},{"key":"10.1016\/j.antiviral.2026.106552_bib45","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1128\/JVI.01406-10","article-title":"Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization","volume":"85","author":"Shi","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2026.106552_bib46","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nsmb964","article-title":"A peptide inhibitor of HIV-1 assembly in vitro","volume":"12","author":"Sticht","year":"2005","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.antiviral.2026.106552_bib47","doi-asserted-by":"crossref","first-page":"5514","DOI":"10.1073\/pnas.0509996103","article-title":"Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor","volume":"103","author":"Stremlau","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2026.106552_bib48","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2026.106552_bib49","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/jac\/dkae115","article-title":"Ultra-rapid selection of the N74D capsid inhibitor resistance mutation after 3 weeks on lenacapavir","volume":"79","author":"Wirden","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2026.106552_bib50","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nature12162","article-title":"Mature HIV-1 capsid structure by cryo-electron microscopy and all-atom molecular dynamics","volume":"497","author":"Zhao","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2026.106552_bib51","doi-asserted-by":"crossref","first-page":"9068","DOI":"10.1128\/JVI.00340-15","article-title":"HIV-1 resistance to the capsid-targeting inhibitor PF74 results in altered dependence on host factors required for virus nuclear entry","volume":"89","author":"Zhou","year":"2015","journal-title":"J. Virol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354226002111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354226002111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:23:24Z","timestamp":1794086604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354226002111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":51,"alternative-id":["S0166354226002111"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2026.106552","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of novel HIV-1 capsid protein (CA) inhibitors (ACAi-010 and ACAi-024) that promote hyper-stabilization of HIV-1 CA in vitro","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2026.106552","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106552"}}